INVIVO THERAPEUTICS HOLDINGS (NVIV) Stock Price & Overview
NASDAQ:NVIV • US46186M6057
Current stock price
The current stock price of NVIV is 0.3207 USD. Today NVIV is down by -34.28%. In the past month the price decreased by -58.69%. In the past year, price decreased by -84.43%.
NVIV Key Statistics
- Market Cap
- 997.377K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.52
- Dividend Yield
- N/A
NVIV Stock Performance
NVIV Stock Chart
NVIV Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NVIV. When comparing the yearly performance of all stocks, NVIV is a bad performer in the overall market: 98.27% of all stocks are doing better.
NVIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVIV. While NVIV has a great health rating, there are worries on its profitability.
NVIV Earnings
NVIV Forecast & Estimates
NVIV Groups
Sector & Classification
NVIV Financial Highlights
Over the last trailing twelve months NVIV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 56.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -97.39% | ||
| ROE | -104.6% | ||
| Debt/Equity | 0 |
NVIV Ownership
NVIV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.46 | 178.493B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.09 | 161.581B | ||
| SYK | STRYKER CORP | 22.42 | 129.785B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.67 | 90.933B | ||
| IDXX | IDEXX LABORATORIES INC | 37.98 | 46.558B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.84 | 45.97B | ||
| BDX | BECTON DICKINSON AND CO | 11.31 | 44.266B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.16 | 33.229B | ||
| RMD | RESMED INC | 18.64 | 33.212B | ||
| DXCM | DEXCOM INC | 25.18 | 25.278B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.98 | 18.201B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 30.46 | 14.039B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVIV
Company Profile
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
Company Info
IPO: 2006-11-14
INVIVO THERAPEUTICS HOLDINGS
Building 1400 East 4Th Floor, One Kendall Square
Cambridge MASSACHUSETTS 02139 US
CEO: Richard Toselli
Employees: 6
Phone: 16178635524
INVIVO THERAPEUTICS HOLDINGS / NVIV FAQ
What does NVIV do?
Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2006-11-14. The firm's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. The company is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
What is the current price of NVIV stock?
The current stock price of NVIV is 0.3207 USD. The price decreased by -34.28% in the last trading session.
Does INVIVO THERAPEUTICS HOLDINGS pay dividends?
NVIV does not pay a dividend.
What is the ChartMill technical and fundamental rating of NVIV stock?
NVIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in INVIVO THERAPEUTICS HOLDINGS be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NVIV.
What is INVIVO THERAPEUTICS HOLDINGS worth?
INVIVO THERAPEUTICS HOLDINGS (NVIV) has a market capitalization of 997.38K USD. This makes NVIV a Nano Cap stock.